校正临床试验长期生存结果误读的方法开发与评估
该研究针对免疫检查点抑制剂(ICI)试验中生存曲线长尾和交叉违反比例风险(PH)假设的问题,提出Cox-TEL校正法,仅需报告的Cox风险比(HR)和Kaplan-Meier生存概率即可将不当Cox HR转换为PH治愈模型效应估计。模拟显示该方法在功效、偏倚和I类错误率方面表现良好,并在黑色素瘤数据集和CheckMate 067试验中验证了校正效果。
要点
- Cox-TEL法仅需Cox HR和KM生存概率即可校正长期生存数据。
- 模拟显示Cox-TEL估计接近PH治愈模型,且用户友好易实现。
- CheckMate 067中Cox HR 0.54经校正为0.90,提示需重新审视ICI试验解读。
核心结论
- Cox-TEL法可将不当Cox HR转换为PH治愈模型治疗效应估计,避免ICI试验长期生存数据的误读。
研究设计与样本
- 方法学研究,采用泰勒展开技术推导Cox PH与PH治愈模型的数学关系,并提出Cox-TEL校正法,仅需Cox HR和Kaplan-Meier生存概率两个输入。
- 通过综合模拟评估方法性能,并在黑色素瘤数据集(N=285)和CheckMate 067试验中验证。
主要发现
- 模拟显示Cox-TEL法在功效、偏倚和I类错误率方面表现良好,结果接近PH治愈模型估计。
- 黑色素瘤数据集中,Cox HR=0.71(95%CI 0.51-0.91),Cox-TEL HR=0.83(95%CI 0.60-1.07),PH cure HR=0.86(95%CI 0.61-1.11);Cox-TEL DP=0.10(95%CI 0.01-0.23),PH cure DP=0.10(95%CI 0.00-0.21)。
- CheckMate 067试验中,Cox HR=0.54(95%CI 0.44-0.67),Cox-TEL HR=0.90(95%CI 0.73-1.11)。
关键数值与推荐
- Cox-TEL法需要报告的Cox HRs和Kaplan-Meier估计的生存概率作为输入。
临床怎么用
- 临床解读ICI试验长期生存数据时,可使用Cox-TEL法校正Cox HR,获得更准确的短期和长期治疗效应估计。
- 该方法用户友好,可通过免费R软件包实现,便于利用已发表临床试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In immune checkpoint inhibitor (ICI) trials, long tails and crossovers in survival curves-which violate the proportional hazards (PH) assumption-are commonly observed, making cure or restricted mean survival time models preferable for analysis of ICI survival data. Cox PH analysis, however, still appears in major medical journals, leading to potential misinterpretation of clinical significance. OBJECTIVE: To convert inappropriate Cox hazard ratios (HRs) to appropriate PH cure model treatment-effect estimates (HR for short-term survivors and difference in proportions [DP] for long-term survivors) for more accurate interpretation of published ICI trials. DESIGN AND SETTING: This study uses the Taylor expansion technique to demonstrate the mathematical relationship between Cox PH and PH cure models for data with long-term survival, and based on this relationship, proposes the Cox-TEL (Cox PH-Taylor expansion adjustment for long-term survival data) adjustment method. The proposed Cox-TEL method requires only 2 inputs: the reported Cox HRs and Kaplan-Meier-estimated survival probabilities. RESULTS: Comprehensive simulations show the strength of the proposed method in terms of power, bias, and type I error rate; these results, which are close to PH cure model estimates, were further verified in a melanoma data set (N = 285; Cox HR = 0.71; 95% CI, 0.51-0.91; Cox-TEL HR = 0.83; 95% CI, 0.60-1.07; PH cure HR = 0.86; 95% CI, 0.61-1.11; Cox-TEL DP = 0.10; 95% CI, 0.01-0.23; PH cure DP = 0.10; 95% CI, 0.00-0.21). The magnitude of potential difference between reported and adjusted HRs using real-world ICI trial results is demonstrated. For example, in the CheckMate 067 trial (nivolumab/ipilimumab combination therapy vs ipilimumab), the Cox HR was 0.54 (95% CI, 0.44-0.67), and the Cox-TEL HR was 0.90 (95% CI, 0.73-1.11). CONCLUSIONS AND RELEVANCE: The findings of this study suggest the need to revisit published ICI survival data analysis to address potential misinterpretation. The Cox-TEL method not only is designed for this purpose, but also is user friendly and easy to implement using published clinical trial data and a freely available R software package.
引用
- Hsu CY, Lin EP, Shyr Y, et al. Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results With Long-term Survival. JAMA Oncol. 2021. PMID: 33856410. doi:10.1001/jamaoncol.2021.0289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。